Glycostem
Phase 1/2We are focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM).
About
We are focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM).
Funding History
3Total raised: $20.5M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile